Sarepta Therapeutics (SRPT) Operating Expenses (2010 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Sarepta Therapeutics was $2.12 billion, down 14.7% year-over-year; for FY2025, it came in at $2.9 billion, up 72.1% from FY2024.

• Annual Operating Expenses has increased for 13 consecutive years, with a five-year compound annual growth rate of 21.3% (FY2020 to FY2025).
• In prior years, Sarepta Therapeutics' Operating Expenses was $1.68 billion in FY2024 (+11.4%), $1.51 billion in FY2023 (+2.9%), $1.47 billion in FY2022 (+26.5%) and $1.16 billion in FY2021 (+5.2%).
• Quarterly Operating Expenses has run from a low of $223.86 million in Q3 2021 to a high of $1.05 billion in Q1 2025 over five years.
• On a year-over-year basis, Operating Expenses increased in six of the last eight quarters, with growth averaging 33.9%.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q1 2025, with growth of 176.1%; the weakest was Q1 2026, with a decline of 64.4%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $372.37 million (Q1 2026), $854.52 million (Q4 2025) and $502.75 million (Q3 2025).